Colin Walsh Sells 105,807 Shares of Attovia Therapeutics (NASDAQ:ATTO) Stock

Posted by Stacy Sanders on Aug 13th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) Director Colin Walsh sold 105,807 shares of Attovia Therapeutics stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $21.28, for a total transaction of $2,251,572.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Colin Walsh also recently made the following trade(s):

On Thursday, August 6th, Colin Walsh bought 500,000 shares of Attovia Therapeutics stock. The stock was purchased at an average price of $17.00 per share, with a total value of $8,500,000.00.

Attovia Therapeutics Stock Performance

ATTO traded up $1.12 during trading hours on Thursday, hitting $19.18. The company’s stock had a trading volume of 406,507 shares, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a fifty-two week low of $16.15 and a fifty-two week high of $22.79.

Institutional Trading of Attovia Therapeutics

An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. increased its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.

About Attovia Therapeutics

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.